We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Moleculin Biotech Inc | NASDAQ:MBRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.19 | -3.77% | 4.85 | 4.85 | 4.98 | 13,907 | 14:16:53 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25 | SEC FILE NUMBER | |
CUSIP NUMBER | ||
NOTIFICATION OF LATE FILING |
(Check one): |
☐
Form 10-K
☐
Form 20-F
☐
Form 11-K
☒
Form 10-Q
☐
Form 10-D
☐ Form N-SAR ☐ Form N-CSR |
For Period Ended:
September 30, 2016
☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: ____________________ |
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
Moleculin Biotech, Inc. |
Full Name of Registrant |
Former Name if Applicable |
2575 West Bellfort, Suite 333 |
Address of Principal Executive Office (Street and Number) |
Houston, Texas 77054 |
City, State and Zip Code |
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
☒ | (a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; | ||
(b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and | |||
(c) | The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III — NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
During the quarter the Company changed its Chief Financial Officer and Jonathan P. Foster became Executive Vice President and Chief Financial Officer of the Company effective August 19, 2016. Due to the change in the principal financial and accounting officer, the Company requires more time to properly and accurately prepare the Form 10-Q for the nine months ended September 30, 2016. Specifically, but not limited to, the Company requires more time to ensure that the technical accounting for its transactions with Moleculin, LLC and Houston Pharmaceuticals, Inc. is properly recorded and disclosed.
PART IV — OTHER INFORMATION
(1) | Name and telephone number of person to contact in regard to this notification | ||||
Jonathan P. Foster, CFO | 713 | 300-5160 | |||
(Name) | (Area Code) | (Telephone Number) | |||
(2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). | ||||
Yes ☒ NO ☐ | |||||
(3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? | ||||
Yes ☒ NO ☐ | |||||
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. The Company is reviewing the technical accounting for its transactions with Moleculin, LLC and Houston Pharmaceuticals, Inc. and, upon such review, there could be a material change to its financial statements for the nine months ended September 30, 2016. At this time the Company cannot identify nor quantify the anticipated change as a result of its review.
|
Moleculin Biotech, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: | 11/15/2016 | By: | /s/ Jonathan P. Foster, CFO |
1 Year Moleculin Biotech Chart |
1 Month Moleculin Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions